Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pomalidomide as an Immune-enhancing Agent for the Control of HIV — Stella

Home/HIV-1 Infection/Pomalidomide as an Immune-enhancing Agent for the Control of HIV

View on ClinicalTrials.gov

Recruiting

Back to HIV-1 Infection trials

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Royal Melbourne Hospital, Melbourne

Denmark

Aarhus University Hospital, Aarhus

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of Aarhus

Enrollment target

~32 participants

Started

May 2025

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.